key: cord-0925904-e5z8ksne authors: Moreno-Torres, Víctor; Muñoz, Alejandro; Calderón-Parra, Jorge; Mills-Sánchez, Patricia; Pintos-Pascual, Ilduara; Rodríguez-Olleros, Celia; Ibánez-Estéllez, Fátima; Tung-Chen, Yale; Ramos-Martínez, Antonio; Vargas-Núñez, Juan A; Cuervas-Mons, Prof. Valentín; de Mendoza, Carmen title: Mortality by Covid-19 Prior to Vaccination - One Year Experience of Hospitalized Patients in Madrid date: 2022-01-22 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2022.01.043 sha: 0a2dfb1571fe22ef763fab1a7d04883565ce296c doc_id: 925904 cord_uid: e5z8ksne Objectives : To analyze the mortality and characteristics of the deceased patients with COVID-19 during the first year of the pandemic. Methods : Analysis of all admissions due to COVID-19 disease in a tertiary hospital in Madrid. Three waves were considered: March to June 2020, July to November 2020 and December 2020 to April 2021. Results : A total of 3,676 patients were identified. Among inpatients, no differences regarding age, sex, admission length or mortality were found between the three waves (p>0.05). The overall mortality rate was 12.9%. Among deceased patients, median age was 82 and the median Charlson co-morbidity index was 6. Considering the main predictors for mortality by COVID-19 (age, sex and concomitant comorbidities), only patients with previous lung disease were more prevalent in the third period (p <0.01). Finally, among deceased patients, higher intensive care unit admission rates, a lower rate of patients coming from nursing homes, and with dementia were noted in the third period (p<0.05). Conclusion : One year after the onset of the pandemic, the mortality rate of hospitalized patients and the profile of non-survivors has not changed significantly. Advanced age and multiple pathologies are uniform characteristics of non-survivors in the absence of the benefit of the vaccines. ARDS: Acute respiratory distress syndrome. CCI: Charlson comorbidity index. ICU: Intensive care unit. SARS-CoV-2 infection is currently the largest health problem worldwide leading to more than 3 million deaths all over the globe during the first year of the pandemic (WHO, 2021) . From the beginning, population studies regarding mortality and susceptible population highlighted that elderly patients, and those who suffered from chronic conditions such as hypertension, diabetes, heart failure, lung disease or immunosuppression, among others, were at higher risk of death Chen et al., 2020] . Similarly, with a 13.8% mortality rate, we confirmed that mortality was strongly related to age and comorbidities during the first wave of COVID-19 in a referral center in Madrid [Moreno-Torres et al., 2021] . Since the pandemic outbreak, different strategies have been implemented in order to reduce the transmission of the virus and its health impact. In the hospital setting, several approaches were tried out to treat the disease in those patients with acute respiratory distress syndrome (ARDS). Among others, dexamethasone, tocilizumab, and anakinra have been shown to be effective in treating severe COVID-19 [Horby et al., 2021; Stone et al., 2020; Kyriazopoulou et al., 2021] . On top of which, the measures introduced of the wearing of facial masks, social distancing and mass lockdowns resulted in fewer hospital admissions. Finally, the rapid development of vaccines led to wide vaccination programs all over the world at the beginning of the year 2021 [Privor-Dumm et al., 2021] . All these factors have resulted in the different waves of the disease that occurred throughout 2020, and have conditioned the variations of the number and the profile of affected individuals. However, there is no data to confirm that the profile of patients with severe COVID-19 and related mortality has changed during the first year of pandemic. Our study analyzes the mortality from COVID-19 in a hospital of reference in Madrid over a year since the start of the pandemic (March 2020 to April 2021), and before the impact of vaccination programs. This retrospective study included all admitted patients with COVID-19 pneumonia at the Puerta de Hierro-Majadahonda University Hospital from March 1 st 2020, to April 30 th 2021. This is a large tertiary university hospital with 613 beds, whose catchment population approaches 375,000 people. The hospital review board approved the study (PI134-20), and a waiver for informed consent was granted. We reviewed electronic medical records for all hospital admitted patients with confirmed COVID-19 disease. The main demographics (gender and age), admission to ICU, and diagnosis discharge (including death if so) were recorded for each one. For all deceased COVID-19 patients, origin (home, nursing homes or referral from other institutions) and the presence of co-morbidities was recorded, including neurocognitive impairment (Alzheimer, other dementias and/or mental disorders), arterial hypertension, diabetes, dyslipidemia, heart disease, cerebrovascular disease, peripheral arterial disease, chronic kidney disease, liver disease, lung disease, cancer, autoimmune diseases and other immunosuppression conditions. The baseline Charlson co-morbidity Index (CCI) was used to estimate the risk of mortality, taking into consideration that the overall 10-year survival rate is 98.3% in patients with a CCI = 0, drops to 77.48% in those with a CCI of 3, and drops further to 21.36% in those with a CCI of 5 or more [Charlson et al., 1987] . In order to examine the course of the pandemic and the changes in patients' profile during the first year after the onset of the pandemic, three different periods were considered: March to June 7 th 2020 (first wave), June 8 th to December 5 th 2020 (second wave) and December 6 th 2020 to April 30 th 2021 (third wave). These dates were selected according to the national restrictions as well as the defined waves seen corresponding to spring 2020, after summer 2020 and from Christmas time up to April 2021. Continuous variables were expressed as mean and standard deviations (SD), and medians with percentiles (P25-P75). Categorical variables were summarized as counts and percentages. The Kolmogorov test was used to evaluate data distribution and the Student ttest or Mann-Whitney U-test were performed consequently to assess differences between groups. Levene´s test was used for the homogeneity of variance test and the χ2 test (with the two-sided Fisher's exact test) was used to compare categorical variables. For all analyses, significance was defined as a P value of less than 0.05. Statistical analysis was performed using the SPSS version 26.0 software statistical package (SPSS Inc., IBM, Armonk, NY). Between March 1 st 2020 and April 30 th 2021, a total of 3,676 patients were hospitalized with COVID-19 at the Hospital Puerta de Hierro-Majadahonda (table 1) . Overall, 60.1% of admitted patients were male and the average age was 65 years-old (54-77). Median length of admission was 8 days (4-14). During the whole study period, 474 patients died (12.9% mortality rate). The hospital admissions during this year were evaluated taking into consideration the three waves ( figure 1, table 1) . Overall, almost a 50% of individuals were included in the first wave (1,788; 48.6%), followed by the second and third wave, with a similar number of individuals in each (926; 25.2% and 962; 26.2%, respectively). When compared, no differences regarding age, sex, admission-length or mortality rates were found. In order to evaluate the differences between the 3 waves of the pandemic, as well as the clinical impact of the measures adopted, we compared the characteristics of the deceased patients. As expected, the mean age of the deceased patients was significantly higher than the age of the survivors (62.8 vs 79.4 years-old, p< 0.001), but no significant differences were noted in the median age of deceased individuals when the 3 periods were compared (82 years-old (72-88)). In addition, no differences were seen regarding sex, length of admission or previous comorbidities, measured as CCI (median 6) (table 2). For previous conditions, only patients with lung disease were more prevalent in the third wave (17.5% vs 5.1% vs 37.1% in the first, second and third wave respectively, p<0.01). On the other hand, non-survivors in the third period presented higher ICU admission rates (12.6% in the first wave, 14.4% in the second wave and 25.8% in the third wave, p<0.03), a lower rate of patients coming from nursing homes (35%, 31.7% and 12.2%, respectively, p<0.001) and a lower rate of dementia (35%, 42.3% and 23.4%, respectively, p<0.02). Similarly, dependence rates were higher in the second period (39.4%, 56.7%, 31.5%, respectively, p<0.01). To note, only 2 patients (1.6%) who died in the third period had received the complete vaccination cycle. The aim of the present study was to analyze the course and the different waves during the first year of COVID-19 pandemic in our hospital, focusing in the epidemiology and characteristics of the deceased patients. After the abrupt irruption of COVID-19 disease, many cohorts worldwide analyzed the mortality rates and the severe disease risk factors, uniformly concluding that frail and comorbid patients were at higher risk Chen et al., 2020; Moreno-Torres et al., 2021] . In addition, once the pandemic stabilized during the summer in 2020, several studies demonstrated that mortality rates significantly improved after the first wave probably because of better understanding of the disease, greater availability of infrastructures, staff or equipment, and the wide use of corticosteroids, among other therapies [Vahidy et al., 2020; Kurtz et al., 2021; Armstrong et al., 2021; Roth et al., 2020; Jones et al., 2021] . However, there is conflicting evidence about the association between these improvements and the changes in the characteristics of the admitted patients. Finally, there is no data about whether the mortality rate and the profile of deceased patients has changed in the last months. Our study reflects that admissions dramatically decreased from the first wave because of the national lockdown and population prophylactic measures adopted in Spain. In addition, it is noticably that each wave presented a peak which was attributed to the greater flexibility and poorer compliance of restrictions during holidays periods such as summer, December national holidays and Christmas . Despite these clearly identifiable dynamics regarding the number of new cases and hospitaladmitted patients, no differences in the deceased patients, by age or gender, were found between the three waves. Moreover, the mortality rate remained constant through the study period, and the profile of the non-survivor individuals remained unchanged. Thus, these results confirm that age and frailty are still by far the strongest risk factors, despite greater knowledge of the disease and better therapeutic management of patients with severe COVID-19. These findings and the discrepancies with others studies could be partially explained with the following reasons. First, broad corticosteroid and tocilizumab treatment was promptly considered in our institution's protocols, leaving less room for improvement in subsequent waves [Fernández-Cruz et al., 2021; Ruiz-Antorán et al., 2021] . Second, early planning and the possibility to double the number of beds per room delayed the early overload of wards and ICUs, contributing to attenuate the mortality rate in comparison with other Spanish hospital cohorts [Moreno-Torres et al., 2021 , Yehia et al., 2020 , Casas-Rojo et al., 2020 . Third, poor knowledge of the natural course of COVID-19 during the first wave resulted in a higher number of hospital admissions for patients who would have benefited from adequate home care. This fact was translated into lower mortality rates at the beginning [Moreno-Torres et al., 2021] . At the same time, the higher number of ICU admissions during the third wave could also be a consequence of the greater severity observed in hospitalized patients during this period. Finally, it should be considered that the majority of the studies carried out during the first wave were based on the diagnosis made in the hospital context . In the following waves, the greater availability of diagnostic tests led to the inclusion of information related to asymptomatic or less severe diagnoses, thus reducing the overall mortality of the infection. Consequently, overall population reported mortality rates could have probably decreased but because a higher number of non-severe patients have been identified, and not necessarily because the disease prognosis has improved. However, our study is based exclusively on the diagnoses that required hospital admission, and on the mortality observed in this setting during the whole study period. Overall, and despite these possible explanations, the fact that mortality rates and the profile of deaths have not changed in one year in our center, yields two possible interpretations. On the one hand, with the therapeutic tools at our disposal, we have managed the disease in an acceptable way from the beginning. On the other hand, these findings emphasize the need for specific antivirals against SARS-CoV-2 [Beigel et al., 2020; Jayk-Bernal et al., 2021; Owen et al., 2021 ]. Finally, it should be mentioned that mass vaccination programs, which began in Madrid at the beginning of the year 2021, have clearly modified the course of severe disease [Barandalla et al., 2021] . In our study, the vaccine impact was intentionally was not yet fully noted, since in April only a small percentage of the population have been fully vaccinated. However, it is observed that during the third wave, the number of dependent and dementia patients was significantly lower than in the previous waves, which can be explained by the impact of the vaccine in these groups. Besides, it is noteworthy that we only identified two deaths in this period who have received the complete vaccination schedule. Altogether, prior data shows that in the absence of effective treatment, the vaccine is an essential tool to reduce mortality from COVID-19 and to prevent the current wave of infections (November 2021) as the one that is occurring in some Central European countries among unvaccinated people. Our analysis has several limitations. First, it is a single-center, observational, retrospective study. Second, we have not analyzed the different therapeutic options and the possible associated benefits. Finally, we have limited ourselves to analyzing the baseline characteristics of the deceased patients, not being able to rule out differences in the total number of hospitalized patients. In conclusion, one year after the onset of the pandemic, the mortality rate of in-hospital patients and the profile of the non-survivors has not varied, being older age and pluripathology constant features of the deceased individuals. Despite the absence of solid improvements in the mortality rates, recent trends might announce the expected benefits of the vaccine. Potential conflicts of interest. The authors declare no conflicts of interest. Funding source. This work has been supported by a grant from Instituto de Salud Carlos III (Expedient number CM19/00223). Ethical Approval Statement. The hospital review board approved the study (PI134-20) and a waiver for informed consent was granted. Mortality rate (%) 13.8 11.2 12.9 12.9 SD: Standard deviation. Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 -Final Report Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry A new method of classifying prognostic comorbidity in longitudinal studies: development and validation Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality Dexamethasone in Hospitalized Patients with Covid-19 Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients Trends in Risk-Adjusted 28-Day Mortality Rates for Patients Hospitalized with COVID-19 in England Evolving changes in mortality of 13,301 critically ill adult patients with COVID-19 over 8 months Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial Major determinants of death in patients hospitalized with COVID-19 during the first epidemic wave in Madrid Mpro inhibitor clinical candidate for the treatment of COVID-19 International Council on Adult Immunization. A global agenda for older adult immunization in the COVID-19 era: A roadmap for action COVID-19: Why Has the Mortality Rate Declined? Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic TOCICOV-study group. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study Main differences between the first and second waves of COVID-19 in Madrid, Spain Third wave of COVID-19 in Madrid, Spain Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 Patients During Initial Peak and Resurgence in the Houston Metropolitan Area World Health Organization. Weekly epidemiological update on COVID-19-27 Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Association of Race With Mortality Among Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) at 92 US Hospitals Age (years) (Median CCI (median ICU: Intensive Care Unit. CCI: Charlson co-morbidity index *p<0.05 (marked with bold): When compared to the other periods The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: